Trial · NCT00090987
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00090987, Phase 2, Completed, AIDS Malignancy Consortium; results first posted 2011-07-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma. Trials, record NCT00090987. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00090987
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
- NCT number
- NCT00090987
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- AIDS Malignancy Consortium
- Conditions
- Sarcoma
- Interventions
- imatinib mesylate
- First posted
- 2004-09-08
- Last updated
- 2018-06-06
- Results first posted
- 2011-07-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients Who Achieve a Clinical Response | 20-24 weeks | Clinical response = Complete Response (absence of residual disease) or Partial Response defined as no new lesions (skin or oral), or no new visceral sites of involvement (or the appearance or worsening of tumor-associated edema or effusions); AND 50% or greater decrease in the number of lesions lasting for \>4 weeks; OR Complete flattening of at least 50% of all previously raised lesions OR A 50% decrease in the sum of the products of the largest perpendicular diameters of the marker lesions |
| Secondary | Inhibition of Platelet-derived Growth Factor-receptor as Assessed by Immunohistochemistry | 12 months | |
| Secondary | Cytokine Profiles Before and After Imatinib Therapy | 12 months | |
| Secondary | Pharmacokinetic Profile of Imatinib and Antiretrovirals | 12 months | |
| Secondary | Mechanisms of Primary and Secondary Resistance to Imatinib Therapy | 12 months | Mutations in the juxtamembrane or kinase membrane of the c-kit or PDGF receptors at baseline or time of progression |
| Secondary | Viral Transcription Profile of Kaposi's Sarcoma-associated Herpesvirus | 12 months |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Patients Who Achieve a Clinical Response | 20-24 weeks | proportion | NUMBER | |
| SECONDARY | Inhibition of Platelet-derived Growth Factor-receptor as Assessed by Immunohistochemistry | 12 months | |||
| SECONDARY | Cytokine Profiles Before and After Imatinib Therapy | 12 months | |||
| SECONDARY | Pharmacokinetic Profile of Imatinib and Antiretrovirals | 12 months | |||
| SECONDARY | Mechanisms of Primary and Secondary Resistance to Imatinib Therapy | 12 months | |||
| SECONDARY | Viral Transcription Profile of Kaposi's Sarcoma-associated Herpesvirus | 12 months |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients Who Achieve a Clinical Response | Imatinib Mesylate (Gleevec) | 0.33 | proportion |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Imatinib Mesylate (Gleevec) | 30 | |
| Overall Study | COMPLETED | Imatinib Mesylate (Gleevec) | 9 | |
| Overall Study | NOT COMPLETED | Imatinib Mesylate (Gleevec) | 21 |
Source ClinicalTrials.gov
Adverse events39
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Metabolism and nutrition disorders | Imatinib Mesylate (Gleevec) | 2 | 30 | 2 |
| other | Alkaline Phosphatase | Metabolism and nutrition disorders | Imatinib Mesylate (Gleevec) | 3 | 30 | 3 |
| other | Amylase | Metabolism and nutrition disorders | Imatinib Mesylate (Gleevec) | 3 | 30 | 10 |
| other | Anorexia | Gastrointestinal disorders | Imatinib Mesylate (Gleevec) | 3 | 30 | 3 |
| other | Blood/Bone Marrow | Blood and lymphatic system disorders | Imatinib Mesylate (Gleevec) | 2 | 30 | 3 |
| other | Bruising | Skin and subcutaneous tissue disorders | Imatinib Mesylate (Gleevec) | 2 | 30 | 2 |
| other | CPK | Metabolism and nutrition disorders | Imatinib Mesylate (Gleevec) | 3 | 30 | 4 |
| other | Constipation | Gastrointestinal disorders | Imatinib Mesylate (Gleevec) | 2 | 30 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Imatinib Mesylate (Gleevec) | 3 | 30 | 4 |
| other | Dermatology/skin, other | Skin and subcutaneous tissue disorders | Imatinib Mesylate (Gleevec) | 2 | 30 | 2 |
1 to 10 of 39Source ClinicalTrials.gov
See all 39 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Imatinib Mesylate (Gleevec) | ||
| Total, other adverse events | Imatinib Mesylate (Gleevec) | 20 | 30 |
| Total, serious adverse events | Imatinib Mesylate (Gleevec) | 2 | 30 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01CA070019 | AMC OPERATIONS CENTER | LEE, JEANNETTE Y. | UNIVERSITY OF ALABAMA AT BIRMINGHAM | NATIONAL CANCER INSTITUTE | 1995 to 2005 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00090987
GET https://conductscience.org/api/trials/v1/NCT00090987/events?page=2